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Bardoxolone Methyl in Type 2 Diabetes and Advanced Chronic 
Kidney Disease
To the Editor: The increased risk of heart fail-
ure and cardiovascular events that led to early 
termination of the BEACON (Bardoxolone Methyl 
Evaluation in Patients with Chronic Kidney Dis-
ease and Type 2 Diabetes Mellitus: the Occur-
rence of Renal Events) trial, reported by de Zeeuw 
et al. (Dec. 26 issue),1 may not be due to direct 
effects of bardoxolone methyl on the cardiovascu-
lar system. The transcription factor Nrf2 (nuclear 
factor [erythroid-derived 2]–related factor 2) is 
known to regulate the expression of multiple drug-
metabolizing enzymes as well as transporters, 
including ABCC2 (multidrug resistance–associat-
ed protein 2),2 which influences the bioavailability 
of angiotensin-receptor blockers.3 Therefore, re-
duced bioavailability of angiotensin-receptor 
blockers or angiotensin-converting–enzyme in-
hibitors (received by approximately 90% of pa-
tients in the BEACON trial) because of increased 
excretion in the bardoxolone methyl group may 
have led to partial loss of the cardioprotective, 
renoprotective, and antihypertensive effects of 
these agents. Nrf2 remains a viable drug target, 
as evidenced by the approval of BG-12 (dimethyl 
fumarate) for multiple sclerosis. In contrast to 
the BEACON trial, the patients enrolled in the 
two phase 3 trials of BG-124,5 were not reported 
to receive other disease-modifying agents; this 
minimized the potential for drug–drug interac-
tions. Future trials of Nrf2 activators in patients 
with chronic diseases who are receiving other 
agents should address potential drug–drug inter-
actions in the preclinical and phase 2 stages.
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To the Editor: With regard to the article by de 
Zeeuw et al. and the corresponding editorial by 
Himmelfarb and Tuttle1: the BEACON study in-
volved patients who had type 2 diabetes mellitus 
and stage 4 chronic kidney disease — a stage in 
which irreversible damage could be detected in 
the majority of nephrons. The remaining neph-
rons in stage 4 chronic kidney disease have hyper-
filtration, which increases proteinuria, and any 
therapy that increases the glomerular filtration 
rate (GFR) aggravates existing single-nephron 
hyperfiltration. In the BEAM (52-Week Bardoxo-
lone Methyl Treatment: Renal Function in CKD/
Type 2 Diabetes)2 and BEACON studies, a bardoxo-
lone-induced increase in GFR could explain the 
increase in proteinuria.
It is feasible that therapy that would decrease 
single-nephron hyperfiltration could prolong 
nephron survival. However, combined renin–angi-
otensin–aldosterone blockade, which decreases 
single-nephron hyperfiltration, did not show ben-
efit (as shown in the Veterans Affairs Nephropa-
thy in Diabetes [VA NEPHRON-D]3 trial and the 
Aliskiren Trial in Type 2 Diabetes Using Cardio-
renal Endpoints [ALTITUDE]4), perhaps because 
earlier initiation of such therapy would be neces-
sary (earlier than stage 3a chronic kidney disease).
The decrease of overt proteinuria and preser-
vation of nephrons should be the true therapeu-
tic goal in patients with diabetes and chronic 
kidney disease, with or without blockade of the 
renin–angiotensin–aldosterone system.
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To the Editor: Himmelfarb and Tuttle, com-
menting on the BEACON trial of bardoxolone in 
diabetic kidney disease, rightly express disap-
pointment at the “failure” of this new treatment. 
They also note the high rate of failure in phase 3 
clinical trials in general, and they argue that bet-
ter approaches to trial design and execution are 
needed. Recently, Djulbegovic and colleagues1 
showed that current trial approaches provide the 
most informative results. These investigators 
analyzed the outcomes of published and unpub-
lished phase 3 randomized clinical trials during 
the past 50 years, and they found that just over 
50% of these trials showed that the new treat-
ment was better than the standard one. Although 
this seems disappointing, they show statistically 
that this modest success rate is the inevitable 
consequence of pretrial equipoise, and that trials 
are most informative when they have only a 50% 
chance of success. Although many aspects of 
clinical-trial design and dissemination can and 
should be improved, negative trial results should 
be lauded as much as positive ones; both advance 
medical science. It is only trials with poor designs 
that do not.
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The Authors Reply: Chartoumpekis and Sykiotis 
are correct that investigators who design clinical 
trials involving patients with chronic diseases 
should be mindful of the potential for drug–drug 
interactions. We also agree that Nrf2 activation 
remains a viable therapeutic target in chronic 
kidney disease. However, there is no evidence 
that the imbalance in adverse effects can be ex-
plained by the mechanism they proposed, since 
the use or nonuse of inhibitors of the renin– 
angiotensin–aldosterone system did not appear 
to modify the effects of bardoxolone methyl.
Molnár and colleagues remind readers of the 
lack of material benefit (i.e., fewer deaths, fewer 
cardiovascular events, or slowing of progression 
of chronic kidney disease) associated with the use 
of dual-agent blockade of the renin–angiotensin–
aldosterone system in diabetic kidney disease, as 
compared with the use of a single agent. We 
would not prioritize clinical trials of two or 
more inhibitors of the renin–angiotensin–aldos-
terone system in chronic kidney disease, with or 
without bardoxolone methyl, given the available 
evidence regarding relative safety and efficacy.
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The Editorialists Reply: Molnár and colleagues 
point to glomerular hyperfiltration to explain 
the results of the BEACON and VA NEPHRON-D 
trials. They suggest that initiating treatment at 
earlier stages of disease might increase the 
chance of therapeutic efficacy. We both served 
on the data and safety monitoring committee in 
the VA NEPHRON-D study and were directly in-
volved with the recommendation for early termi-
nation because of safety concerns. Since both the 
BEACON and VA NEPHRON-D trials were termi-
nated early because of adverse safety signals, the 
efficacy of these approaches has not been com-
pletely determined, even in the study populations. 
It is possible that the safety of the respective 
therapeutic strategies could be improved by re-
stricting enrollment to patients at an earlier stage 
of disease and at lower risk for adverse events. A 
search for therapies that can provide synergistic 
benefit with moderate inhibition of the renin–
angiotensin system is clearly an ongoing high 
priority for improving outcomes in patients with 
diabetic kidney disease.
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Ellison notes that ethical clinical trials should 
be testing hypotheses based on equipoise; thus, 
we should expect approximately 50% of trials to 
support the null hypothesis, whereby a new treat-
ment will not prove to be better than a standard 
one. We agree completely with this philosophical 
premise and recognize that a well-designed and 
well-conducted “null study” is a successful trial. 
The treatment of diabetic kidney disease would 
have greatly advanced over the past several de-
cades if 50% of relevant clinical trials had shown 
efficacy, which unfortunately has not been the 
case. Within the framework of equipoise, every 
effort should be made to maximize patient safety, 
which should always be the paramount concern 
in study design. The BEACON trial was termi-
nated early because of strong adverse safety 
signals in study participants who received bar-
doxolone methyl as compared with those who 
received placebo. The study did not continue 
long enough to fully determine the efficacy of 
the drug for slowing the progression of diabetic 
kidney disease. We continue to emphasize the 
need for greater rigor in preclinical testing, care-
ful evaluations of dosing, improved methods for 
off-target toxicity testing, and biomarker develop-
ment. We also stress the need for business and 
regulatory environments that foster innovation. 
Other authors have also recently called for simi-
lar approaches to improving the drug-develop-
ment process.1-3
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Overall Survival in Renal-Cell Carcinoma with Pazopanib  
versus Sunitinib
To the Editor: In the August 22 issue,1 we re-
ported on a phase 3 trial showing the noninfe-
riority, with respect to progression-free survival, 
of pazopanib versus sunitinib as first-line treat-
ment for clear-cell, metastatic renal-cell carci-
noma, as assessed by independent review. We 
now report the results of the final analysis of 
overall survival. Overall survival, a secondary end 
point, was defined as the time from randomiza-
tion to death from any cause. The final analysis 
of overall survival in the intention-to-treat popu-
lation was to be performed when 650 patients 
had died or 2 years after the last patient was en-
rolled. Overall survival was summarized by means 
of Kaplan–Meier curves and compared with the 
use of a stratified log-rank test. The strata were 
baseline Karnofsky performance-status score 
(70 or 80 vs. 90 or 100 on a scale from 0 to 100, 
with 100 indicating normal functioning and lower 
scores indicating increasing disability), baseline 
level of lactate dehydrogenase (>1.5 vs. ≤1.5 times 
the upper limit of the normal range), and previ-
ous nephrectomy (yes vs. no).
At data cutoff on September 30, 2013, a total 
of 334 of 557 patients who were randomly as-
signed to pazopanib (60%) and 335 of 553 pa-
tients who were randomly assigned to sunitinib 
(61%) had died. Overall survival was similar in 
the two groups (hazard ratio for death with pa-
zopanib vs. sunitinib, 0.92; 95% confidence in-
terval [CI], 0.79 to 1.06; P = 0.24 by a stratified 
log-rank test) (Fig. 1). Median overall survival 
was 28.3 months in the pazopanib group (95% 
CI, 26.0 to 35.5) and 29.1 months in the suni-
tinib group (95% CI, 25.4 to 33.1).
Subgroup analyses according to Memorial 
Sloan-Kettering Cancer Center risk criteria2 
showed a median overall survival of 42.5 months 
among 151 patients who received pazopanib 
(95% CI, 37.9 to not reached) and 43.6 months 
among 152 patients who received sunitinib (95% 
CI, 37.1 to 47.4) in a group of patients with favor-
able-risk disease (hazard ratio for death with 
pazopanib, 0.88; 95% CI, 0.63 to 1.21). The me-
dian overall survival was 26.9 months among 
322 patients who received pazopanib (95% CI, 
23.1 to 35.6) and 26.1 months among 328 patients 
who received sunitinib (95% CI, 20.7 to 31.6) in 
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